Addressing Colonoscopy Quality to Increase Capacity for Colorectal Cancer Screening (CCSG YR13)
Addressing Colonoscopy Quality to Increase Capacity for Colorectal Cancer Screening (CCSG YR13)
批准号:
10893842
负责人:
Carlos L Arteaga
金额:
$4.93万
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
未结题
起止时间:
2010-09-01 至 2026-07-31
关键词:
Academic Medical CentersAddressAdvisory CommitteesAgeAreaCancer Center Support GrantCancer EtiologyCessation of lifeColonoscopyColorectalColorectal CancerCommunitiesComplementDataDetectionDiagnosticEarly DiagnosisEffectivenessEndoscopyEnsureFamily PracticeFrequenciesGeographyGoalsGuidelinesHealth Services AccessibilityIncidenceIndividualInformation SystemsInterventionIntestinesIntubationKnowledgeLinkLiteratureModelingNorth DakotaOperative Surgical ProceduresOregonOutcomePatientsPerformancePhysiciansPopulationProbabilityProviderRecommendationReportingResearchResidenciesResourcesResponse ElementsRuralRural CommunityServicesSocietiesStandardizationTestingTexasTimeTrainingTraining ProgramsUnited StatesUniversitiesWithdrawalWorkadenomacancer diagnosisclinical practicecolorectal cancer screeningcost effectivenessfollow-upimprovedinstrumentmedical specialtiesmortalityoutreachprogramsquality assurancescreeningscreening guidelinesscreening programscreening servicessuburburban area
中文摘要
结直肠癌(CRC)是美国第三大确诊癌症。建议进行常规结直肠癌筛查
英文摘要
Colorectal cancer (CRC) is the third most diagnosed cancer in the United States. Routine CRC screening is recommended
for individuals ages 45 and older, but is only effective when completed appropriately, like completing diagnostic
colonoscopy after a fecal immunochemical test (FIT). Effectiveness is further impacted by colonoscopy quality. In 2007, a
standardized colonoscopy reporting and data system (CO-RADS) was developed using the key indicators for continuous
quality improvement identified by the Multi-Society Task Force on Colorectal Cancer (MSTF-CRC). Based on the
literature, some variability in the quality of colonoscopy provided in clinical practice is expected, but there is an urgent
need to standardize colorectal early detection screening services, particularly as we consider how best to address
colonoscopy capacity issues in underserved settings.
Our long-term goal is to ensure the quality of colonoscopies in communities where capacity may be limited. Our overall
objective is to determine what resources for colorectal cancer screening are available and the quality of service by a
range of provider specialties and types. Our rationale for the proposed research is e to improve the effectiveness of
colonoscopies in CRC screenings by impacting cecal intubation rates, adenoma detection rates, mean withdrawal time,
and adequate bowel preps.
We plan to accomplish our overall objective for this project through the following three specific aims:
1. Identify the challenges for colonoscopy completion in rural geography. The emphasis in this aim is gaining
the knowledge about service availability and patient need from a population perspective.
2. Examine providers’ alignment with guideline recommendations for screening and frequency. The study
focus of this aim is the variability in screening performance based on provider type.
3. Developing a new endoscopy training program for physicians completing a general surgery residency. The
training program will address the major areas of improvement needed based on the findings from the
previous aims.
With respect to outcomes, we expect to identify the full complement of response elements which determine the overall
quality of colorectal cancer screening services. Such results are expected to vertically advance the outcomes of screening
interventions and maximize cost-effectiveness. Equally important, the results are expected to have a positive impact
because it is probable this highly specific and sensitive training model will save resources that are currently strained.
期刊论文(714)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Overcoming endosomal barrier by amphotericin B-loaded dual pH-responsive PDMA-b-PDPA micelleplexes for siRNA delivery.
通过两性霉素B负载双pH响应PDMA-B-PDPA胶束胶束来克服内体屏障,用于siRNA递送。
DOI:
10.1021/nn203503h
发表时间:
2011-11-22
期刊:
ACS nano
影响因子:
17.1
作者:
[Yu H, Zou Y, Wang Y, Huang X, Huang G, Sumer BD, Boothman DA, Gao J]
通讯作者:
Gao J
Dynamic bioluminescence and fluorescence imaging of the effects of the antivascular agent Combretastatin-A4P (CA4P) on brain tumor xenografts.
抗血管剂Combretastatin-A4p(CA4P)对脑肿瘤异种移植物的影响的动态生物发光和荧光成像。
DOI:
10.1016/j.canlet.2014.09.038
发表时间:
2015-01-28
期刊:
Cancer letters
影响因子:
9.7
作者:
[Liu L, Mason RP, Gimi B]
通讯作者:
Gimi B
DOI:
10.1038/nnano.2017.52
发表时间:
2017-07
期刊:
Nature nanotechnology
影响因子:
38.3
作者:
[Luo M, Wang H, Wang Z, Cai H, Lu Z, Li Y, Du M, Huang G, Wang C, Chen X, Porembka MR, Lea J, Frankel AE, Fu YX, Chen ZJ, Gao J]
通讯作者:
Gao J
DOI:
10.1016/j.jconrel.2020.06.030
发表时间:
2020-09-10
期刊:
Journal of controlled release : official journal of the Controlled Release Society
影响因子:
--
作者:
[Xiong H, Liu S, Wei T, Cheng Q, Siegwart DJ]
通讯作者:
Siegwart DJ
DOI:
10.1166/jbn.2014.1949
发表时间:
2014-08
期刊:
Journal of biomedical nanotechnology
影响因子:
2.9
作者:
[Liu L, Su X, Mason RP]
通讯作者:
Mason RP
共 455 条
Neoadjuvant Neratinib in Stage I-III HER2-mutated Lobular Breast Cancer
-
批准号:10660734
-
项目类别:
-
资助金额:$51.03万
-
财政年份:2023
-
负责人:Carlos L Arteaga
-
依托单位:
Role of HER2 mutations in breast cancer progression and response to targeted therapies
-
批准号:9759820
-
项目类别:
-
资助金额:$35.74万
-
财政年份:2018
-
负责人:Carlos L Arteaga
-
依托单位:
Role of HER2 mutations in breast cancer progression and response to targeted therapies
-
批准号:10214565
-
项目类别:
-
资助金额:$36.83万
-
财政年份:2018
-
负责人:Carlos L Arteaga
-
依托单位:
Role of HER2 mutations in breast cancer progression and response to targeted therapies
-
批准号:10458531
-
项目类别:
-
资助金额:$36.09万
-
财政年份:2018
-
负责人:Carlos L Arteaga
-
依托单位:
Role of HER2 mutations in breast cancer progression and response to targeted therapies
-
批准号:9614453
-
项目类别:
-
资助金额:$38.26万
-
财政年份:2018
-
负责人:Carlos L Arteaga
-
依托单位:
Admin/Outreach Core
-
批准号:8947587
-
项目类别:
-
资助金额:$7.77万
-
财政年份:2014
-
负责人:Carlos L Arteaga
-
依托单位:
Inhibition of P13 Kinase as a Strategy to Abrogate Antiestrogen Resistance in Br
-
批准号:8764757
-
项目类别:
-
资助金额:$27.75万
-
财政年份:2014
-
负责人:Carlos L Arteaga
-
依托单位:
Developmental Research Program
-
批准号:8764765
-
项目类别:
-
资助金额:$6.58万
-
财政年份:2014
-
负责人:Carlos L Arteaga
-
依托单位:
Career Development Program
-
批准号:8764766
-
项目类别:
-
资助金额:$6.58万
-
财政年份:2014
-
负责人:Carlos L Arteaga
-
依托单位:
UT Southwestern Medical Center Simmons Comprehensive Cancer Center
-
批准号:10693201
-
项目类别:
-
资助金额:$430.61万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
UT Southwestern Medical Center Simmons Comprehensive Cancer Center
-
批准号:10170609
-
项目类别:
-
资助金额:$430.61万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
UT Southwestern Medical Center Simmons Comprehensive Cancer Center
-
批准号:10477948
-
项目类别:
-
资助金额:$430.61万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
Developmental Funds
-
批准号:10477999
-
项目类别:
-
资助金额:$47.07万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
Cancer Center Administration Core
-
批准号:10703661
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
Population Science and Cancer Control Scientific Program
-
批准号:10260732
-
项目类别:
-
资助金额:$2.82万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
PLANNING AND EVALUATION (Core-001)
-
批准号:10260746
-
项目类别:
-
资助金额:$4.09万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
Administrative Core and Senior Leadership
-
批准号:10260747
-
项目类别:
-
资助金额:$23.61万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
Cancer Center Administration Core
-
批准号:10693202
-
项目类别:
-
资助金额:$43.7万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
Leadership, Planning, and Evaluation
-
批准号:10170620
-
项目类别:
-
资助金额:$56.26万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
Cancer Center Support Grant - UT Southwestern Medical Center
-
批准号:9906340
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2010
-
负责人:Carlos L Arteaga
-
依托单位:
海外基金